Superior limbic keratoconjunctivitis

disease
On this page

Also known as SLKsuperior limbal keratoconjunctivitisTheodore's superior limbic keratoconjunctivitisTheodore's syndromeTheodores superior limbic keratoconjunctivitisTheodores syndrome

Summary

Superior limbic keratoconjunctivitis (MONDO:0019504) is a disease and 3 clinical trials. A subtype of keratoconjunctivitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namesuperior limbic keratoconjunctivitis
Mondo IDMONDO:0019504
Orphanet88633
ICD-111962803547
SNOMED CT231903005
UMLSC0339229
MedGen573037
GARD0010940
Is cancer (heuristic)no

Also known as: SLK · superior limbal keratoconjunctivitis · Theodore’s superior limbic keratoconjunctivitis · Theodore’s syndrome · Theodores superior limbic keratoconjunctivitis · Theodores syndrome

Disease family

This is a subtype of keratoconjunctivitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye disordercorneal disorderkeratitiskeratoconjunctivitissuperior limbic keratoconjunctivitis

Related subtypes (6): phlyctenulosis, neurotrophic keratoconjunctivitis, punctate epithelial keratoconjunctivitis, epidemic keratoconjunctivitis, exposure keratitis, dry eye syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified3

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00167050Not specifiedUNKNOWNThe Pathogenesis of Superior Limbic Keratoconjunctivitis
NCT02160327Not specifiedUNKNOWNThe Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye
NCT03731624Not specifiedUNKNOWNDiadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.